Policy Watch: HHS moves to keep more drug trials in the US

The United States has long set the global standard for pharmaceutical innovation and regulatory rigor.But the global pharmaceutical landscape is more competitive than ever, with other countries designing their regulatory systems and clinical research infrastructure to lure early-stage clinical investment away from the U.S. It is critical to protect clinical research in the U.S. because it ensures that American patients will continue to have earlier access to new therapies and are protected by the world's most advanced regulatory oversight.